[144] Electromed, Inc. SEC Filing
Electromed, Inc. (ELMD) Form 144 reports a proposed sale of 65,714 shares of common stock via BTIG, LLC on the NYSE American with an aggregate market value of $1,554,136.10. The shares were acquired in the open market on 06/01/2021 and paid for in cash. The filing lists 8,349,176 shares outstanding for the class and shows no securities sold in the past three months. The proposed sale is scheduled for 09/10/2025. The filer affirms there is no undisclosed material adverse information.
- Regulatory compliance: Filing clearly discloses the proposed sale and required acquisition/payment details under Rule 144
- Transaction provenance: Shares were acquired in the open market and paid in cash, reducing concerns about non-cash consideration
- Attestation provided: Filer represents no known undisclosed material adverse information
- None.
Insights
TL;DR: Insider or affiliated holder plans a modest open-market sale of 65,714 shares worth $1.55M; compliance disclosed properly.
The filing documents a planned open-market disposition executed through BTIG, LLC with clear acquisition and payment dates. The position represents a small percentage of the stated outstanding shares, suggesting limited immediate dilution or market impact. The absence of any sales in the prior three months reduces the likelihood of an ongoing accelerated sell program. This is a routine Form 144 disclosure consistent with regulatory requirements.
TL;DR: The notice is a standard disclosure; it confirms representation about lack of undisclosed material information.
The filer includes the customary attestation that no material nonpublic information is known and provides transaction provenance (open market acquisition, cash payment). The scheduled sale date and broker identification meet procedural expectations for Rule 144 notices. From a governance perspective, the form fulfils transparency obligations but does not provide role or insider status of the seller.